Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 357-400

  Danhof, Meindert ^a,b   De Jongh, Joost ^a,b   De Lange, Elizabeth C M ^a   Della Pasqua, Oscar ^a,c   Ploeger, Bart A ^a,b   Voskuyl, Rob A ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Disease progression; Functional adaptation; Operational model of agonism; Pharmacodynamic interaction; Target site distribution; Transduction

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ALFENTANIL; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOBAZAM; CORTICOSTEROID DERIVATIVE; FENTANYL; FLESINOXAN; FLUNITRAZEPAM; GLICLAZIDE; METFORMIN; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR AGONIST; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; OXAZEPAM; PIOGLITAZONE; SEROTONIN ANTAGONIST; SUFENTANIL;

DISEASE COURSE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG TARGETING; DYNAMIC SYSTEMS ANALYSIS; FEEDBACK SYSTEM; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEM ANALYSIS; THEORY;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION;

EID: 33847028671     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105154     Document Type: Review

References (122)

1. Breimer DD, Danhof M. 1997. The relevance of PK-PD modeling in drug development: the wooden shoe paradigm. Clin. Pharmacokin. 32:259-67
2. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, et al. 1994. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34:111-19
3. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. 2005. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22:1432-37
4. 1 receptors. J. Pharmacol. Exp. Ther. 283:809-16
5. A receptor modulators: in vitro-in vivo correlations. J. Pharmacol. Exp. Ther. 304:88-101
6. Lepist EI, Jukso WJ. 2004. Modeling and allometric scaling of S(+) ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J. Vet. Pharmacol. Ther. 27:211-18
7. Rowland M, Balant LP, Peck CC. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. AAPS Pharm. Sci. 6:E6
8. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. 1995. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J. Pharmacokinet. Biopharm. 23:217-29
9. Pulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:1358-70
10. Nesterov IA. 2003. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42:883-908
11. Sheiner LB, Stanski DR, Voseh S, Miller RD, Ham J. 1979. Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to D-tubocurarine. Clin. Pharmacol. Ther. 25:358-71
12. Fuseau E, Sheiner LB. 1984. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther. 35:733-41
13. Unadkat JD, Bartha F, Sheiner LB. 1986. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric pharmacokinetic and pharmacodynamic models. Clin. Pharmacol. Ther. 40:86-93
14. Veng-Pedersen P, Mandema JW, Danhof M. 1991. A system approach to pharmacodynamics III. An algorithm and computer program COLAPS for pharmacodynamic modeling. J. Pharm. Sci. 80:488-95
15. Veng-Pedersen P, Modi B. 1992. Pharmacodynamic system analysis of the biophase level predictor and the transduction function. J. Pharm. Sci. 81:925-34
16. Danhof M, Van der Graaf PH, Jonker DM, Visser SAG, Zuideveld KP. 2006. Mechanism-based pharmacokinetic-pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships-application in drug candidate selection and lead optimization. In Comprehensive Medicinal Chemistry-II, in press. Amsterdam: Elsevier
17. Stanski DR, Ham J, Miller RD, Sheiner LB. 1979. Pharmacokinetics and pharmacodynamics of D-tubocurarine during nitrous oxide-narcotic and halothane anesthesia. Anesthesiology 51:235-41
18. Mandema JW, Veng-Pedersen P, Danhof M. 1992. Estimation of amobarbital plasma effect site equilibration kinetics. Relevance of poly-exponential conductance functions. J. Pharmacokin. Biopharm. 19:617-34
19. Visser SAG, Smulders JGM, Reijers BPR, Van der Graaf PH, Peletier LA, Danhof M. 2002. Mechanism-based pharmacokinetic-pharmacodynamic modelling of concentration-dependent hysteresis and biphaseic electroencephalogram effects of alphaxalone in rats. J. Pharmacol. Exp. Ther. 302:1158-67
20. 1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J. Pharmacol. Exp. Ther. 308:1012-20
21. Mandema JW, Sansom LN, Dios-Vièitez MC, Hollander-Jansen M, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther. 257:472-78
22. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the μ-opioid receptor. J. Pharmacol. Exp. Ther. 284:1095-103
23. Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the polyspecific organic cation transporters: OTC1,2 and 3 (SLC22a1-3). J. Pharmacol. Exp. Ther. 308:2-9
24. De Lange EC, Danhof M. 2 002. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokin. 41:691-703
25. De Boer AG, Van der Sandt IC, Gaillard PJ. 2003. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43:629-56
26. Lee G, Dallas S, Hong M, Bendayan. 2001. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:569-96
27. Letrent SP, Pollack GM, Brouwer KR, Brouwer KC. 1998. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:599-605
28. De Lange EC, Danhof M, De Boer AG, Breimer DD. 1997. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on blood-brain barrier transport of drugs. Brain Res. 25:27-49
29. Xie R, Hammarlund-Udenaes M, De Boer AG, De Lange EC. 1999. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a(-/-) and mdr1a(+/+) mice. Br. J. Pharmacol. 128:563-68
30. Hammarlund-Udenaes M. 2000. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug. Deliv. Rev. 45:283-94
31. Hammarlund-Udenaes M, Paalzow LK, De Lange ECM. 1997. Drug equilibration across the blood-brain barrier: pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 14:128-34
32. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M. 2001. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br. J. Pharmacol. 134:1796-804
33. Van der Graaf PH, Danhof M. 1997. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int. J. Clin. Pharmacol. Ther. 35:442-46
34. Stephenson RP. 1956. A modification of receptor theory. Br. J. Pharmacol. 11:379-93
35. Furchgott RF. 1966. The use of beta-haloakylamines in the differentiation of receptors and the determination of dissociation constants of receptor agonist complexes. In Advances in Drug Research, pp. 21-55. New York: Academic
36. Tuk B, Van Oostenbruggen MF, Herben VMM, Mandema JW, Danhof M. 1999. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J. Pharmacol. Exp. Ther. 289:1067-74
37. Black JW, Leff P. 1983. Operational models of pharmacological agonism. Proc. R. Soc. London B 220:141-62
38. Leff P, Prentice DJ, Giles H, Martin GR, Wood J. 1990. Estimation of agonist affinity and efficacy by direct, operational model fitting. J. Pharmacol. Toxicol. Methods 23:225-37
39. Barlow RB, Scott NC, Stephenson RP. 1967. The affinity and efficacy of onium salts on the frog recrus abdominis. Br. J. Pharmacol. Chemother. 31:188-96
40. 1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. 290:702-9
41. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the μ-opioid receptor. J. Pharmacol. Exp. Ther. 284:1095-103
42. Garrido M, Gubbens-Stibbe JM, Tukker HJ, Cox EH, Von Freitag Drabbe Künzel J, et al. Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following β-funaltrexamine-induced μ-opioid receptor knockdown in vivo. Pharm. Res. 17:653-59
43. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. 2005. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin. Pharmacol. Ther. 77:572-82
44. Deleted in proof
45. 6- cyclopentyladenosine (CPA) in the rat. J. Pharmacol. Exp. Ther. 268:616-24
46. 6-(-p-sulfophenyl) adenosine in rats. Br. J. Pharmacol. 122:525-33
47. 1 receptor in vivo. Br. J. Pharmacol. 116:1957-64
48. 1 receptor in vivo. J. Pharmacol. Exp. Ther. 279:1439-46
49. 1 receptor agonists. J. Pharmacokin. Biopharm. 25:673-94
50. 6-cyclopentyl adenosine in vivo: hemodynamic versus antilipolytic responses in rats. Br. J. Pharmacol. 124:607-18
51. Cox EH, Van Hemert JGM, Tukker HJ, Danhof M. 1997. Pharmacokinetic- pharmacodynamic modelling of the EEG effect of alfentanil in rats. J. Pharmacol. Toxicol. Meth. 38:99-108
52. Scott JC, Ponganis KV, Stanski DR. 1985. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 62:234-41
53. Scott JC, Cooke JE, Stanski DR. 1991. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 74:34-42
54. Egan TD, Minto CF, Herrmann DJ, Barr J, Muir KT, Shafer SL. 1996. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy male volunteers. Anesthesiology 84:821-33
55. Cox EH, Langemeijer MWE, Gubbens-Stibbe JM, Muir KT, Danhof M. 1999. The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat EEG model. Anesthesiology 90:535-40
56. Cox EH, Kuipers JA, Danhof M. 1998. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. Br. J. Pharmacol. 124:1534-40
57. Waldhoer M, Bartlett S, Whistler JL. 2004. Opioid receptors. Annu. Rev. Biochem. 73:953-90
58. Deleted in proof
59. Mandema JW, Tukker HJ, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br. J. Pharmacol. 102:663-68
60. Mandema JW, Kuck MT, Danhof M. 1992. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br. J. Pharmacol. 105:164-70
61. Mandema JW, Tukker E, Danhof M. 1992. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260:36-44
62. Mandema JW, Kuck MT, Danhof M. 1992. In vivo modelingof the pharmacodynamic interaction between benzodiazepines which differ in intrinsic activity. J. Pharmacol. Exp. Ther. 261:56-61
63. Mandema JW, Danhof M. 1992. EEG effect measures and relationships between pharmacokinetics and pharmacodynamics of psychotropic drugs. Clin. Pharmacokin. 23:191-215
64. Breimer LTM, Hennis PJ, Burm AGL, Danhof M, Bovill JG, et al. 1990. Quantification of the EEG effect of midazolam in volunteers: pharmacokinetic-pharmacodynamic modelling. Clin. Pharmacokin. 18:245-53
65. Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. 1992. Pharmacokinetic-pharmacodynamic modelling of the CNS effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 51:715-28
66. Laurijssens BE, Greenblatt DJ. 1996. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin. Pharmacokinet. 30:52-76
67. Cox EH, Knibbe CAJ, Koster VS, Langemeijer MWE, Tukker HE, et al. 1998. Influence of different fat emulsion based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm. Res. 15:442-48
68. A receptor in vivo. J. Pharmacol. Exp. Ther. 303:616-26
69. Cleton A, De Greef HJMM, Edelbroek PM, Voskuyl RA, Danhof M. 1999. Application of a combined "effect compartment/indirect response model" to the central nervous system effect of tiagabine in the rat. J. Pharmacokinet. Biopharm. 27:301-23
70. Anderson A, Boyd AC, Byford A, Campbell AC, Gemmell DK, et al. 1997. Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors. J. Med. Chem. 40:1668-81
71. Visser SAG, Wolters FLC, Gubbens-Stibbe JM, Tukker E, Van der Graaf PH, et al. 2003. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J. Pharmacol. Exp. Ther. 304:88-101
72. Haefely WE, Martin JR, Richards JG, Schoch P. 1993. The multiplicity of actions of benzodiazepine receptor ligands. Can. J. Psychiat. 38(Suppl. 4):S102-8
73. Sieghart W. 1992. GABAA receptors: ligand-gated Cl- ion channels modulated by multiple drug-binding sites. Trends Pharmacol. Sci. 13:446-50
74. Chou TC, Tallay P. 1984. Quantitative analysis of dose effect relationships. Adv. Enzyme. Reg. 22:27-55
75. Berenbaum MC. 1989. What is synergy? Pharm. Rev. 41:93-141
76. Koizumi T, Kakemi M, Katayama K. 1983. Kinetics of combined drug action. J. Pharmacokin. Biopharm. 21:593-607
77. Gessner PK. 1995. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161-79
78. Carter WH. 1995. Relating isobolograms to response surfaces. Toxicology 105:181-88
79. Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from response surface perspective. Pharm. Rev. 47:331-85
80. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. 2000. Response surface model for anesthetic drug interactions. Anesthesiology 92:1603-16
81. Jonker DM, Visser SAG, Van der Graaf PH, Voskuyl RA, Danhof M. 2005. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106:1-18
82. Ariens EJ, Van RossumJM, Simonis AM. 1956. A theoretical basis of molecular pharmacology. Part I. Interactions of one or two compounds with one receptor system. Arzneimit. Schung. 6:282-93
83. Ehlert FJ. 1988. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33:187-94
84. Tuk B, Van Oostenbrugge MF, Herben VMM, Mandema JW, Danhof M. 1999. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J. Pharmacol. Exp. Ther. 289:1067-74
85. 6-cyclopentyladenosine and 8-cyclopentyltheophylline. Br. J. Pharmacol. 115:1253-59
86. Zuideveld KP, Treijtel N, Maas HJ, Gubbens-Stibbe JM, Peletier LA, et al. 2002. A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. J. Pharm. Exp. Ther. 300:330-38
87. Zuideveld KP, Rusic-Pavletic J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M. 2002. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J. Pharmacol. Exp. Ther. 303:1130-37
88. Breimer LTM, Burm AGL, Danhof M, Hennis PJ, Vletter AA, et al. 1991. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers with aperiodic EEG analysis Clin. Pharmacokin. 20:497-508
89. Hoyo-Vadillo C, Mandema JW, Danhof M. 1995. Synergistic pharmacodynamic interaction between midazolam and low doses of ethanol in vivo. Life Sci. 57:325-34
90. Tuk B, Van Gool T, Danhof M. 2002. Mechanism-based pharmacodynamic modelling of the interaction of midazolam, bretazenil and zolpidem with ethanol. J. Pharmacokin. Pharmacodyn. 29:235-50
91. Jonker DM, Vermeij DA, Edelbroek PM, Voskuyl RA, Piotrovsky VK, Danhof M. 2003. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. Epilepsia 44(3):329-38
92. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-78
93. Mager DE, Wyska E, Jusko WJ. 2003. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Disp. 31:510-19
94. Sun YN, Jusko WJ. 1998. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 87:732-37
95. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. 2002. Fifth generation model for corticosteroid pharmacodynamics: application to steady-state receptor down regulation and enzyme induction patterns during seven day continuous infusion of methylpresnisolone in rats. J. Pharmacokin. Pharmacodyn. 29:1-24
96. Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. 2005. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J. Clin. Oncol. 23:413-21
97. Jin JY, Almon RR, Dubois DC, Jusko WJ. 2003. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J. Pharmacol. Exp. Ther. 307:93-109
98. Jin JY, Dubois DC, Almon RR, Jusko WJ. 2004. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J. Pharmacol. Exp. Ther. 309:328-39
99. Zuideveld KP, Maas HJ, Treijtel N, Hulshof J, Van der Graaf PH, et al. 2001. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am. J. Physiol. Reg. Integr. Comp. Physiol. 281: R2059-71
100. Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD. 1987. Rate of increase in plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin. Pharmacol. Ther. 41:26-30
101. Bauer JA, Fung HL. 1994. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11:816-23
102. Eckblad EB, Licko V. 1984. A model eliciting transient responses. Am. J. Physiol. Reg. Integr. Comp. Physiol. 264:R114-21
103. Mandema JW, Wada DR. 1995. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Ther. 279:1035-42
104. Veng Pedersen P, Modi NB. 1993. A system approach to pharmacodynamics. Input-effect control system analysis of the central nervous system effect of alfentanil. J. Pharm. Sci. 82:266-72
105. Äbelö A, Eriksson UG, Karlsson MO, Larsson H, Gabrielsson J. 2000. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J. Pharmacol. Exp. Ther. 295:662-69
106. Francheteau P, Steimer JL, Merdjan H, Guerret M, Dubray C. 1993. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J. Pharmacokin. Biopharm. 21:489-514
107. Yu H, Liu Y, Malmberg A, Mohell N, Hacksell U, Lewer T. 1996. Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin. Eur. J. Pharmacol. 303:151-62
108. Zeisberger E. 1998. Biogenic amines and thermoregulatory changes. Prog. Brain Res. 115:159-76
109. Bligh J. 1974. Recent Studies of Hypothalamic Function, ed. K Lederis, KE Cooper, pp. 315-27. Calgary, Can.: S. Krager
110. Cabanac M. 1975. Temperature regulation. Annu. Rev. Physiol. 37:415-39
111. Boeckman A, Sheiner LB, Beal SL. 1992. NONMEM Users Guide, NONMEM Project Group. San Francisco: Univ. Calif.
112. 1A-receptor agonist flesinoxan. Eur. J. Pharmacol. 445:43-54
113. Van der Sandt ICJ, Smolders R, Nabulsi L, Zuideveld KP, De Boer AG, Breimer DD. 2001. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur. J. Pharm. Sci. 14:81-86
114. Visser SAG, Pozarek S, Martinsson S, Forsberg T, Ross SB, Gabrielsson J. 2005. Rapid and long-lasting tolerance to clomethiazole-induced hypothermia in the rat. Eur. J. Pharmacol. 512:139-51
115. Sällström B, Visser SAG, Forsberg T, Peletier LA, Ericson AC, Gabrielsson J. 2005. A pharmacodynamic turnover model encapturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal handling effects. J. Pharmacokin. Pharmacodyn. 32:835-59
116. Chan PL, Holford NHG. 2001. Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41:625-59
117. Holford NHG, Peace KE. 1992. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. USA 89:11466-70
118. Post TM, Freijer JI, De Jongh J, Danhof M. 2005. Disease system analysis: basic disease progression models in degenerative disease. Pharm. Res. 22:1038-49
119. De Winter W, De Jongh J, Post T, Ploeger B, Urquhart R, et al. 2006. A mechanism-based disease progression model for comparison of the long-term effects of pioglitazone, meformin and glyclazide on disease processes underlying type 2 diabetes mellitus. J. Pharmacokin. Pharmacodyn. 33:13-43
120. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Turner RC. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-19
121. UK Prospective Diabetes Study Group. 1998. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-53
122. UK Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854-65